Opioid Use DisorderRISE-CMNCT07322588
Reentry Incentives and Support for Engagement With Contingency Management
A study testing Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) Intervention in people with Opioid Use Disorder, run by Oregon Health and Science University at 1 site in United States.
Trial summary
People leaving jail face a very high risk of overdose, especially in the first few weeks after release. Staying on medication for opioid use disorder (MOUD) can greatly reduce this risk, but many people stop treatment during this transition. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Opioid Use Disorder
- What is being tested?
- Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) Intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 75 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2026to 30 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be adults (age ≥18 years) currently incarcerated at Clatsop County Jail
- Be enrolled in the jail's MOUD program at the time of recruitment
- Plan to continue MOUD with Clatsop Behavioral Healthcare upon release
- Speak English and be able to provide informed consent
Who cannot join
- Are unable to provide informed consent due to cognitive impairment or acute psychiatric instability
- Are scheduled for transfer to a different facility or geographic location that prevents post-release participation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Clatsop County Corrections
Warrenton, Oregon, 97146
Thomas Teague Jail Commander, 5033258641, tteague@clatsopcounty.gov
About this study
Official title: Enhancing Medication for Opioid Use Disorder Retention With Post-Release Contingency Management
People leaving jail face a very high risk of overdose, especially in the first few weeks after release. Staying on medication for opioid use disorder (MOUD) can greatly reduce this risk, but many people stop treatment during this transition. This study is testing whether a program that offers rewards, called contingency management (CM), can help people stay on MOUD after they return to the community.
In this study, people who are taking MOUD in jail can choose to participate. While still incarcerated, they complete one visit where they may receive a small incentive, such as commissary credit or snacks, for enrolling in the CM program. After they leave jail, participants can earn gift cards when they attend their MOUD appointments and counseling sessions.
Read more
Participants may take part in the study for up to three months after release. During this time, they can earn up to $600 in incentives based on their treatment engagement. Researchers will also ask participants to complete a baseline survey and a survey at 3 months. We will also review medical records to confirm whether they continued their MOUD.
The researchers want to learn whether this adapted contingency management program is feasible, acceptable to participants, and helpful for supporting treatment engagement after release from jail. The findings will help determine whether this approach should be tested in a larger study to reduce overdose risk and improve health during the post-release period.
- Conditions
- Opioid Use Disorder
- Being tested
- Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) Intervention
- Keywords
- contingency management, opioid use disorder, incarceration, reentry
- Medical subject headings
- Opioid-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) InterventionOther
Participants receive gift card rewards for attending MOUD appointments and counseling appointments after release from incarceration.
| Study group | Role | What they receive |
|---|---|---|
| RISE-CM Intervention | Other | All participants are enrolled in the intervention arm. Receives: Other: Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients receiving medication for opioid use disorder
We will assess patient reported receipt of medication for opioid use disorder and also use chart review to determine whether patients are receiving medications and three different time points.
Measured: 1, 2, and 3 months
Secondary outcomes (4)
Number of contingency management sessions attended
Number of contingency management sessions attended per participant
Measured: 3 months
Total contingency management rewards earned
Total dollar amount of contingency management rewards earned by participant throughout the intervention
Measured: 3 months
Addiction Severity
Participant reported addiction severity using the validated Brief Addiction Monitor, a 17-item, multidimensional progress monitoring tool designed to support the provision of measurement-based care to patients commencing and matriculating through treatment for substance use disorders (SUD). The BAM items assess: (1) Risk for relapse or worsening severity of SUD (Range 0-180 with higher scores indicating higher risk), (2) Protective behaviors that support recovery and resistance to relapse (Range 0-180 with higher score indicating higher protective factors), and (3) Use of alcohol and other substances (Range 0-90 with higher score indicating higher substance use).
Measured: Baseline and 3 months
Recovery Capital
Participant reported survey on recovery capital using the validated "Brief Assessment of Recovery Capital (BARC-10)" survey. Score range 10-60 with higher scores indicating higher recovery capital.
Measured: Baseline and 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2026
- Study start1 Jan 2026 (estimated)
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Opioid Use DisorderStudies of the same condition, open and under way.
- More trials run by Oregon Health and Science UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oregon Health and Science University
- Sponsor type
- University, hospital or other
- Collaborators
- Clatsop Behavioral Healthcare, Oregon Health Authority, Clatsop County Corrections
- Responsible party
- Principal investigator, Linda Peng, Oregon Health and Science University
- Investigators
- Linda Peng, MD, Principal investigator, Oregon Health and Science University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07322588
- Sponsor's protocol ID
- STUDY00028902
- Other IDs
- Agreement #184714
- Acronym
- RISE-CM
- Status last verified
- Dec 2025
- First submitted
- 1 Dec 2025
- Last updated
- 7 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Enhancing Medication for Opioid Use Disorder Retention With Post-Release Contingency Management
- ClinicalTrials.gov ID
- NCT07322588
- Acronym / sponsor ID
- RISE-CM / STUDY00028902
- Conditions
- Opioid Use Disorder
- Keywords
- contingency management, opioid use disorder, incarceration, reentry
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- Oregon Health and Science UniversityUniversity, hospital or other
- Collaborators
- Clatsop Behavioral Healthcare, Oregon Health Authority, Clatsop County Corrections
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 7 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
People leaving jail face a very high risk of overdose, especially in the first few weeks after release. Staying on medication for opioid use disorder (MOUD) can greatly reduce this risk, but many people stop treatment during this transition. This study is testing whether a program that offers rewards, called contingency management (CM), can help people stay on MOUD after they return to the community.
In this study, people who are taking MOUD in jail can choose to participate. While still incarcerated, they complete one visit where they may receive a small incentive, such as commissary credit or snacks, for enrolling in the CM program. After they leave jail, participants can earn gift cards when they attend their MOUD appointments and counseling sessions.
Participants may take part in the study for up to three months after release. During this time, they can earn up to $600 in incentives based on their treatment engagement. Researchers will also ask participants to complete a baseline survey and a survey at 3 months. We will also review medical records to confirm whether they continued their MOUD.
The researchers want to learn whether this adapted contingency management program is feasible, acceptable to participants, and helpful for supporting treatment engagement after release from jail. The findings will help determine whether this approach should be tested in a larger study to reduce overdose risk and improve health during the post-release period.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| RISE-CM Intervention | Other | Other: Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) InterventionAll participants are enrolled in the intervention arm. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Be adults (age ≥18 years) currently incarcerated at Clatsop County Jail
- Be enrolled in the jail's MOUD program at the time of recruitment
- Plan to continue MOUD with Clatsop Behavioral Healthcare upon release
- Speak English and be able to provide informed consent
Key exclusion criteria (2 listed)
- Are unable to provide informed consent due to cognitive impairment or acute psychiatric instability
- Are scheduled for transfer to a different facility or geographic location that prevents post-release participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) InterventionParticipants receive gift card rewards for attending MOUD appointments and counseling appointments after release from incarceration. | Other | RISE-CM Intervention |
Primary outcome
Number of patients receiving medication for opioid use disorder
Time frame: 1, 2, and 3 months
We will assess patient reported receipt of medication for opioid use disorder and also use chart review to determine whether patients are receiving medications and three different time points.
4 secondary outcomes
Number of contingency management sessions attended
Time frame: 3 months
Total contingency management rewards earned
Time frame: 3 months
Addiction Severity
Time frame: Baseline and 3 months
Recovery Capital
Time frame: Baseline and 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Opioid Use Disorder
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Not yet recruiting
Comprehensive Opioid Management and Breathing During Sleep
Sleep-Disordered Breathing, Chronic Opioid Use
Active, not recruitingPhase 2
Wellcome Leap Psilocybin for OUD
Opioid Use Disorder
Recruiting
Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial
Opioid Use Disorder, Opioid Misuse
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Linda Peng, MD principal investigator
Oregon Health and Science University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) Intervention in people with Opioid Use Disorder, run by Oregon Health and Science University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Carol DeFrancesco Senior Research Associate (5033105036, defrance@ohsu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients receiving medication for opioid use disorder (time frame: 1, 2, and 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.